Year |
Citation |
Score |
2024 |
Al-Ghabkari A, Huang B, Park M. Aberrant Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions. Cells. 13. PMID 38334610 DOI: 10.3390/cells13030218 |
0.304 |
|
2024 |
Zhu X, Fu Z, Dutchak K, Arabzadeh A, Milette S, Steinberger J, Morin G, Monast A, Pilon V, Kong T, Adams BN, Prando Munhoz E, Hosein HJ, Fang T, Su J, ... ... Park M, et al. Co-targeting CDK4/6 and BRD4 promotes senescence and ferroptosis sensitivity in cancer. Cancer Research. PMID 38277141 DOI: 10.1158/0008-5472.CAN-23-1749 |
0.314 |
|
2023 |
Goyette MA, Duhamel S, Aubert L, Pelletier A, Savage P, Thibault MP, Johnson RM, Carmeliet P, Basik M, Gaboury L, Muller WJ, Park M, Roux PP, Gratton JP, Côté JF. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression. Cell Reports. 42: 113604. PMID 38100352 DOI: 10.1016/j.celrep.2023.113604 |
0.348 |
|
2023 |
Nandi I, Smith HW, Sanguin-Gendreau V, Ji L, Pacis A, Papavasiliou V, Zuo D, Nam S, Attalla SS, Kim SH, Lusson S, Kuasne H, Fortier AM, Savage P, Martinez Ramirez C, ... Park M, et al. Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression. The Journal of Clinical Investigation. PMID 36795481 DOI: 10.1172/JCI162324 |
0.314 |
|
2022 |
Pathmanathan S, Yao Z, Coelho P, Valla R, Drecun L, Benz C, Snider J, Saraon P, Grozavu I, Kotlyar M, Jurisica I, Park M, Stagljar I. B cell linker protein (BLNK) is a regulator of Met receptor signaling and trafficking in non-small cell lung cancer. Iscience. 25: 105419. PMID 36388990 DOI: 10.1016/j.isci.2022.105419 |
0.375 |
|
2022 |
Coelho PP, Park M. LEAP: a novel LC3C-dependent pathway connects autophagy, endocytic trafficking and signaling. Autophagy. PMID 36026467 DOI: 10.1080/15548627.2022.2117973 |
0.344 |
|
2022 |
Coelho PP, Hesketh GG, Pedersen A, Kuzmin E, Fortier AN, Bell ES, Ratcliffe CDH, Gingras AC, Park M. Endosomal LC3C-pathway selectively targets plasma membrane cargo for autophagic degradation. Nature Communications. 13: 3812. PMID 35780247 DOI: 10.1038/s41467-022-31465-3 |
0.317 |
|
2022 |
Stern YE, Al-Ghabkari A, Monast A, Fiset B, Aboualizadeh F, Yao Z, Stagljar I, Walsh LA, Duhamel S, Park M. Met-HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells. Cellular and Molecular Life Sciences : Cmls. 79: 178. PMID 35249128 DOI: 10.1007/s00018-022-04149-w |
0.406 |
|
2021 |
Kuzmin E, Monlong J, Martinez C, Kuasne H, Kleinman CL, Ragoussis J, Bourque G, Park M. Inferring Copy Number from Triple-Negative Breast Cancer Patient Derived Xenograft scRNAseq Data Using scCNA. Methods in Molecular Biology (Clifton, N.J.). 2381: 285-303. PMID 34590283 DOI: 10.1007/978-1-0716-1740-3_16 |
0.322 |
|
2021 |
Sung VYC, Knight JF, Johnson RM, Stern YE, Saleh SM, Savage P, Monast A, Zuo D, Duhamel S, Park M. Co-dependency for MET and FGFR1 in basal triple-negative breast cancers. Npj Breast Cancer. 7: 36. PMID 33772015 DOI: 10.1038/s41523-021-00238-4 |
0.354 |
|
2020 |
Zaoui K, Smith HW, Park M, Duhamel S. ARF6 controls RHOB targeting to endosomes regulating cancer cell invasion. Molecular & Cellular Oncology. 7: 1766932. PMID 32944628 DOI: 10.1080/23723556.2020.1766932 |
0.51 |
|
2020 |
Wu Q, Ba-Alawi W, Deblois G, Cruickshank J, Duan S, Lima-Fernandes E, Haight J, Tonekaboni SAM, Fortier AM, Kuasne H, McKee TD, Mahmoud H, Kushida M, Cameron S, Dogan-Artun N, ... ... Park M, et al. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer. Nature Communications. 11: 4205. PMID 32826891 DOI: 10.1038/S41467-020-18020-8 |
0.402 |
|
2020 |
Mohammad AH, Kim SH, Bertos N, El-Assaad W, Nandi I, Smith H, Yang J, Chen O, Gamache I, Rao T, Gagnon B, Gruosso T, Tremblay ML, Sonenberg N, Guiot MC, ... ... Park M, et al. Elevated V-ATPase activity following PTEN loss is required for enhanced oncogenic signaling in breast cancer. Molecular Cancer Research : McR. PMID 32587106 DOI: 10.1158/1541-7786.Mcr-20-0088 |
0.422 |
|
2020 |
Xue Y, Zhu X, Meehan B, Venneti S, Martinez D, Morin G, Itoua Maïga R, Chen H, Papadakis AI, Johnson RM, O'Sullivan MJ, Erdreich-Epstein A, Gotlieb WH, Park M, Judkins AR, et al. SMARCB1 loss induces druggable cyclin D1 deficiency via upregulation of MIR17HG in atypical teratoid rhabdoid tumors. The Journal of Pathology. PMID 32558936 DOI: 10.1002/Path.5493 |
0.313 |
|
2020 |
Deblois G, Madani Tonekaboni SA, Grillo G, Martinez C, Kao YI, Tai F, Ettayebi I, Fortier AM, Savage P, Fedor AN, Liu X, Guilhamon P, Lima-Fernandes E, Murison A, Kuasne H, ... ... Park M, et al. Epigenetic switch-induced viral mimicry evasion in chemotherapy resistant breast cancer. Cancer Discovery. PMID 32546577 DOI: 10.1158/2159-8290.Cd-19-1493 |
0.308 |
|
2020 |
Vernier M, Dufour CR, McGuirk S, Scholtes C, Li X, Bourmeau G, Kuasne H, Park M, St-Pierre J, Audet-Walsh E, Giguère V. Estrogen-related receptors are targetable ROS sensors. Genes & Development. PMID 32079653 DOI: 10.1101/Gad.330746.119 |
0.342 |
|
2020 |
Bell ES, Coelho PP, Park M. LC3C mediates selective autophagy of the MET RTK, inhibiting cancer cell invasion. Autophagy. 1-3. PMID 32065021 DOI: 10.1080/15548627.2020.1728099 |
0.493 |
|
2020 |
Jiang HY, Najmeh S, Martel G, MacFadden-Murphy E, Farias R, Savage P, Leone A, Roussel L, Cools-Lartigue J, Gowing S, Berube J, Giannias B, Bourdeau F, Chan CHF, Spicer JD, ... ... Park M, et al. Activation of the pattern recognition receptor NOD1 augments colon cancer metastasis. Protein & Cell. PMID 31956962 DOI: 10.1007/S13238-019-00687-5 |
0.474 |
|
2020 |
Gruosso T, Park M, Levine H, Li X. Abstract B65: Mathematical modeling studies on spatial profiles of tumor-infiltrating T cells Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-B65 |
0.324 |
|
2020 |
Pathmanathan S, Yao Z, Snider J, Drecun L, Benz C, Stern Y, Park M, Stagljar I. Mapping the MET Receptor Tyrosine Kinase Interactome using Mammalian Membrane Two Hybrid (MaMTH) system The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.03394 |
0.41 |
|
2019 |
Bell ES, Coelho PP, Ratcliffe CDH, Rajadurai CV, Peschard P, Vaillancourt R, Zuo D, Park M. LC3C-Mediated Autophagy Selectively Regulates the Met RTK and HGF-Stimulated Migration and Invasion. Cell Reports. 29: 4053-4068.e6. PMID 31851933 DOI: 10.1016/J.Celrep.2019.11.063 |
0.549 |
|
2019 |
Hirukawa A, Singh S, Wang J, Rennhack JP, Swiatnicki M, Sanguin-Gendreau V, Zuo D, Daldoul K, Lavoie C, Park M, Andrechek ER, Westbrook TF, Harris LN, Varadan V, Smith HW, et al. Reduction of Global H3K27me Enhances HER2/ErbB2 Targeted Therapy. Cell Reports. 29: 249-257.e8. PMID 31597089 DOI: 10.1016/J.Celrep.2019.08.105 |
0.374 |
|
2019 |
Zaoui K, Rajadurai CV, Duhamel S, Park M. Arf6 regulates RhoB subcellular localization to control cancer cell invasion. The Journal of Cell Biology. PMID 31591185 DOI: 10.1083/Jcb.201806111 |
0.426 |
|
2019 |
Kong T, Xue Y, Cencic R, Zhu X, Monast A, Fu Z, Pilon V, Sangwan V, Guiot MC, Foulkes WD, Porco JA, Park M, Pelletier J, Huang S. eIF4A inhibitors suppress cell cycle feedback response and acquired resistance to CDK4/6 inhibition in cancer. Molecular Cancer Therapeutics. PMID 31395685 DOI: 10.1158/1535-7163.Mct-19-0162 |
0.397 |
|
2019 |
Smith HW, Hirukawa A, Sanguin-Gendreau V, Nandi I, Dufour CR, Zuo D, Tandoc K, Leibovitch M, Singh S, Rennhack JP, Swiatnicki M, Lavoie C, Papavasiliou V, Temps C, Carragher NO, ... ... Park M, et al. An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. Nature Communications. 10: 2901. PMID 31263101 DOI: 10.1038/S41467-019-10681-4 |
0.379 |
|
2019 |
Gruosso T, Gigoux M, Manem VSK, Bertos N, Zuo D, Perlitch I, Saleh SMI, Zhao H, Souleimanova M, Johnson RM, Monette A, Ramos VM, Hallett MT, Stagg J, Lapointe R, ... ... Park M, et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. The Journal of Clinical Investigation. PMID 30753167 DOI: 10.1172/Jci96313 |
0.307 |
|
2019 |
Li X, Gruosso T, Zuo D, Omeroglu A, Meterissian S, Guiot MC, Salazar A, Park M, Levine H. Infiltration of CD8 T cells into tumor cell clusters in triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 30733298 DOI: 10.1073/Pnas.1817652116 |
0.324 |
|
2019 |
Xue Y, Meehan B, Macdonald E, Venneti S, Wang XQD, Witkowski L, Jelinic P, Kong T, Martinez D, Morin G, Firlit M, Abedini A, Johnson RM, Cencic R, Patibandla J, ... ... Park M, et al. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nature Communications. 10: 558. PMID 30718512 DOI: 10.1038/S41467-018-06958-9 |
0.444 |
|
2019 |
Bareche Y, Buisseret L, Gruosso T, Girard E, Venet D, Dupont F, Desmedt C, Park M, Rothé F, Stagg J, Sotiriou C. Abstract P4-06-03: Unravelling triple-negative breast cancer tumor microenvironment heterogeneity using an integrative multiomic analysis Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P4-06-03 |
0.333 |
|
2018 |
Zaoui K, Duhamel S, Parachoniak CA, Park M. CLIP-170 spatially modulates receptor tyrosine kinase recycling to coordinate cell migration. Traffic (Copenhagen, Denmark). PMID 30537020 DOI: 10.1111/Tra.12629 |
0.818 |
|
2018 |
Ratcliffe CDH, Siddiqui N, Coelho PP, Laterreur N, Cookey TN, Sonenberg N, Park M. HGF-induced migration depends on the PI(3,4,5)P-binding microexon-spliced variant of the Arf6 exchange factor cytohesin-1. The Journal of Cell Biology. PMID 30404949 DOI: 10.1083/Jcb.201804106 |
0.522 |
|
2018 |
Murali B, Ren Q, Luo X, Faget DV, Wang C, Johnson RM, Gruosso T, Flanagan KC, Fu Y, Leahy KM, Alspach E, Su X, Ross MH, Burnette B, Weilbaecher KN, ... Park M, et al. Inhibition of the stromal p38MAPK/MK2 pathway limits breast cancer metastases and chemotherapy-induced bone loss. Cancer Research. PMID 30093561 DOI: 10.1158/0008-5472.Can-18-0234 |
0.373 |
|
2018 |
Sizemore GM, Balakrishnan S, Thies KA, Hammer AM, Sizemore ST, Trimboli AJ, Cuitiño MC, Steck SA, Tozbikian G, Kladney RD, Shinde N, Das M, Park D, Majumder S, Krishnan S, ... ... Park M, et al. Stromal PTEN determines mammary epithelial response to radiotherapy. Nature Communications. 9: 2783. PMID 30018330 DOI: 10.1038/S41467-018-05266-6 |
0.385 |
|
2018 |
Hirukawa A, Smith HW, Zuo D, Dufour CR, Savage P, Bertos N, Johnson RM, Bui T, Bourque G, Basik M, Giguère V, Park M, Muller WJ. Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. Nature Communications. 9: 2547. PMID 29959321 DOI: 10.1038/S41467-018-04864-8 |
0.302 |
|
2018 |
Dankner M, Lajoie M, Moldoveanu D, Nguyen TT, Savage P, Rajkumar S, Huang X, Lvova M, Protopopov A, Vuzman D, Hogg D, Park M, Guiot MC, Petrecca K, Mihalcioiu C, et al. Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29903896 DOI: 10.1158/1078-0432.Ccr-17-3384 |
0.351 |
|
2018 |
Goyette MA, Duhamel S, Aubert L, Pelletier A, Savage P, Thibault MP, Johnson RM, Carmeliet P, Basik M, Gaboury L, Muller WJ, Park M, Roux PP, Gratton JP, Côté JF. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression. Cell Reports. 23: 1476-1490. PMID 29719259 DOI: 10.1016/J.Celrep.2018.04.019 |
0.396 |
|
2018 |
Knight JF, Sung VYC, Kuzmin E, Couzens AL, de Verteuil DA, Ratcliffe CDH, Coelho PP, Johnson RM, Samavarchi-Tehrani P, Gruosso T, Smith HW, Lee W, Saleh SM, Zuo D, Zhao H, ... ... Park M, et al. KIBRA (WWC1) Is a Metastasis Suppressor Gene Affected by Chromosome 5q Loss in Triple-Negative Breast Cancer. Cell Reports. 22: 3191-3205. PMID 29562176 DOI: 10.1016/J.Celrep.2018.02.095 |
0.334 |
|
2018 |
Robichaud N, Hsu BE, Istomine R, Alvarez F, Blagih J, Ma EH, Morales SV, Dai DL, Li G, Souleimanova M, Guo Q, Del Rincon SV, Miller WH, Ramón Y Cajal S, Park M, et al. Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils. Proceedings of the National Academy of Sciences of the United States of America. PMID 29463754 DOI: 10.1073/Pnas.1717439115 |
0.446 |
|
2018 |
Hirukawa A, Smith H, Zou D, Savage P, Johnson R, Bourque G, Giguere V, Basik M, Dufour C, Park M, Muller W. Abstract B46: Targeting EZH2 reactivates a breast cancer subtype-specific antimetastatic transcriptional program Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-B46 |
0.301 |
|
2018 |
Gruosso T, Gigoux M, Bertos N, Manem V, Zuo D, Saleg S, Souleimanova M, Zhao H, Johnson R, Monette A, Ramos VM, Hallett M, Stagg J, Lapointe R, Omeroglu A, ... ... Park M, et al. Abstract PD6-05: Distinct tumor microenvironments stratify triple negative breast cancer into immune subtypes Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd6-05 |
0.32 |
|
2018 |
Li R, Couturier C, Savage P, Monlong J, Bourque G, Petrecca K, Park M, Ragoussis J. Abstract 2177: Sensitive single cell copy number profiling using a novel microfluidic droplet based platform Cancer Research. 78: 2177-2177. DOI: 10.1158/1538-7445.Am2018-2177 |
0.366 |
|
2018 |
Kuasne H, Savage P, Ramirez CM, Liu L, Muñoz-Ramos V, Pilon V, Monast A, Johnson R, Bertos N, Asselah J, Bouganim N, Petrecca K, Meterissian S, Omeroglu A, Basik M, ... Park M, et al. Abstract 1044: Establishment and characterization of rare breast patient-derived xenograft models as a potential resource for personalized medicine Cancer Research. 78: 1044-1044. DOI: 10.1158/1538-7445.Am2018-1044 |
0.335 |
|
2017 |
Savage P, Blanchet-Cohen A, Revil T, Badescu D, Saleh SMI, Wang YC, Zuo D, Liu L, Bertos NR, Munoz-Ramos V, Basik M, Petrecca K, Asselah J, Meterissian S, Guiot MC, ... ... Park M, et al. A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer. Cell Reports. 21: 1140-1149. PMID 29091754 DOI: 10.1016/J.Celrep.2017.10.015 |
0.425 |
|
2017 |
Grandal MM, Havrylov S, Poulsen TT, Koefoed K, Dahlman A, Galler GR, Conrotto P, Collins S, Eriksen KW, Kaufman D, Vande Woude GF, Jacobsen HJ, Horak ID, Kragh M, Lantto J, ... ... Park M, et al. Simultaneous targeting of two distinct epitopes on MET effectively inhibits MET- and HGF-driven tumor growth by multiple mechanisms. Molecular Cancer Therapeutics. PMID 28802255 DOI: 10.1158/1535-7163.Mct-17-0374 |
0.362 |
|
2017 |
Saleh SM, Bertos NR, Gruosso T, Gigoux M, Souleimanova M, Zhao H, Omeroglu A, Hallett MT, Park M. Identification of interacting stromal axes in triple-negative breast cancer. Cancer Research. PMID 28652250 DOI: 10.1158/0008-5472.Can-16-3427 |
0.321 |
|
2017 |
Liu H, Dowdle JA, Khurshid S, Sullivan NJ, Bertos N, Rambani K, Mair M, Daniel P, Wheeler E, Tang X, Toth K, Lause M, Harrigan ME, Eiring K, Sullivan C, ... ... Park M, et al. Discovery of Stromal Regulatory Networks that Suppress Ras-Sensitized Epithelial Cell Proliferation. Developmental Cell. 41: 392-407.e6. PMID 28535374 DOI: 10.1016/J.Devcel.2017.04.024 |
0.439 |
|
2017 |
Shafer ME, Nguyen AH, Tremblay M, Viala S, Béland M, Bertos NR, Park M, Bouchard M. Lineage Specification from Prostate Progenitor Cells Requires Gata3-Dependent Mitotic Spindle Orientation. Stem Cell Reports. PMID 28285879 DOI: 10.1016/J.Stemcr.2017.02.004 |
0.364 |
|
2017 |
Savage P, Saleh S, Wang Y, Revil T, Badescu D, Liu L, Iacucci E, Zuo D, Bertos N, Munoz-Ramos V, Asselah J, Meterissian S, Omeroglu A, Hébert S, Kleinman C, ... Park M, et al. Abstract P1-06-11: A targetable EGFR-driven tumor-initiating program in breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-06-11 |
0.31 |
|
2017 |
Jandaghi P, Najafabadi HS, Bauer A, Papadakis AI, Fassan M, Hall A, Monast A, Safisamghabadi M, Doeberitz MvK, Neoptolemos JP, Costello E, Greenhalf W, Scarpa A, Sipos B, Auld D, ... ... Park M, et al. Abstract 1135: DRD2 is critical for pancreatic cancer and promises pharmacological therapy by already established antagonists Cancer Research. 77: 1135-1135. DOI: 10.1158/1538-7445.Am2017-1135 |
0.323 |
|
2016 |
Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, ... ... Park M, et al. Corrigendum: Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nature Medicine. 22: 1192. PMID 27711065 DOI: 10.1038/Nm1016-1192C |
0.338 |
|
2016 |
Rajadurai CV, Havrylov S, Coelho PP, Ratcliffe CD, Zaoui K, Huang BH, Monast A, Chughtai N, Sangwan V, Gertler FB, Siegel PM, Park M. 5'-Inositol phosphatase SHIP2 recruits Mena to stabilize invadopodia for cancer cell invasion. The Journal of Cell Biology. PMID 27597754 DOI: 10.1083/Jcb.201501003 |
0.4 |
|
2016 |
Bertos NR, Park M. Laser Capture Microdissection as a Tool to Study Tumor Stroma. Methods in Molecular Biology (Clifton, N.J.). 1458: 13-25. PMID 27581011 DOI: 10.1007/978-1-4939-3801-8_2 |
0.312 |
|
2016 |
Deblois G, Smith HW, Tam IS, Gravel SP, Caron M, Savage P, Labbé DP, Bégin LR, Tremblay ML, Park M, Bourque G, St-Pierre J, Muller WJ, Giguère V. ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer. Nature Communications. 7: 12156. PMID 27402251 DOI: 10.1038/Ncomms12156 |
0.37 |
|
2016 |
Ratcliffe CD, Sahgal P, Parachoniak CA, Ivaska J, Park M. Regulation of cell migration and β1 integrin trafficking by the endosomal adaptor GGA3. Traffic (Copenhagen, Denmark). PMID 26935970 DOI: 10.1111/Tra.12390 |
0.803 |
|
2016 |
Boulay PL, Mitchell L, Turpin J, Huot-Marchand JÉ, Lavoie C, Sanguin-Gendreau V, Jones L, Mitra S, Livingstone JM, Campbell S, Hallett M, Mills GB, Park M, Chodosh L, Strathdee D, et al. Rab11-FIP1C is a critical negative regulator in ErbB2-mediated mammary tumor progression. Cancer Research. PMID 26933086 DOI: 10.1158/0008-5472.Can-15-2782 |
0.374 |
|
2016 |
Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, ... ... Park M, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nature Medicine. PMID 26779812 DOI: 10.1038/Nm.4032 |
0.418 |
|
2016 |
Lee J, Bainer R, Frankenberger C, Rabe D, Saleh s, Park M, An G, Gilad Y, Rosner MR. Abstract B15: Metastatic breast tumors regulate gene expression at distal mammary sites that predicts patient outcome Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Metca15-B15 |
0.335 |
|
2016 |
Saleh S, Gruosso T, Gigoux M, Bertos N, Omeroglu A, Zuo D, Meterissian S, Hallett M, Park M. Abstract IA23: Deconvolution of the triple-negative breast cancer microenvironment Cancer Research. 76. DOI: 10.1158/1538-7445.Tme16-Ia23 |
0.336 |
|
2016 |
Gruosso T, Gigoux M, Bertos N, Saleh S, Omeroglu A, Zuo D, Zhao H, Souleimanova M, Weaver V, Meterissian S, Hallett M, Park M. Abstract A15: Mechanisms of CD8+ T cell immunosuppression in triple negative breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Tme16-A15 |
0.352 |
|
2016 |
Thompson C, Saleh SM, Bertos N, Gigoux M, Gruosso T, Souleimanova M, Zhao H, Hallett MT, Park M. Abstract 720: Novel prognostic stromal subtypes in triple-negative breast cancer Cancer Research. 76: 720-720. DOI: 10.1158/1538-7445.Am2016-720 |
0.342 |
|
2016 |
Ragoussis I, Savage P, Wang Y, Revil T, Badescu D, Saleh S, Iacucci E, Bertos N, Monast A, Omeroglou A, Zuo D, Park M. Abstract 2386: Microfluidic single cell exome-seq and RNA-seq analysis of tumor composition Cancer Research. 76: 2386-2386. DOI: 10.1158/1538-7445.Am2016-2386 |
0.367 |
|
2015 |
Kim BR, Lee SH, Park MS, Seo SH, Park YM, Kwon YJ, Rho SB. MARCKSL1 exhibits anti-angiogenic effects through suppression of VEGFR-2-dependent Akt/PDK-1/mTOR phosphorylation. Oncology Reports. PMID 26555156 DOI: 10.3892/or.2015.4408 |
0.364 |
|
2015 |
Jang EJ, Jeong HO, Park D, Kim DH, Choi YJ, Chung KW, Park MH, Yu BP, Chung HY. Src Tyrosine Kinase Activation by 4-Hydroxynonenal Upregulates p38, ERK/AP-1 Signaling and COX-2 Expression in YPEN-1 Cells. Plos One. 10: e0129244. PMID 26466383 DOI: 10.1371/journal.pone.0129244 |
0.406 |
|
2015 |
Li J, Davidson D, Souza CM, Zhong MC, Wu N, Park M, Muller WJ, Veillette A. Loss of PTPN12 stimulates progression of ErbB2-dependent breast cancer by enhancing cell survival, migration and epithelial-to-mesenchymal transition. Molecular and Cellular Biology. PMID 26391955 DOI: 10.1128/Mcb.00741-15 |
0.41 |
|
2015 |
Caserta E, Egriboz O, Wang H, Martin C, Koivisto C, Pecót T, Kladney RD, Shen C, Shim KS, Pham T, Karikomi MK, Mauntel MJ, Majumder S, Cuitino MC, Tang X, ... ... Park M, et al. Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo. Genes & Development. 29: 1707-20. PMID 26302789 DOI: 10.1101/Gad.262568.115 |
0.369 |
|
2015 |
Oh EY, Christensen SM, Ghanta S, Jeong JC, Bucur O, Glass B, Montaser-Kouhsari L, Knoblauch NW, Bertos N, Saleh SM, Haibe-Kains B, Park M, Beck AH. Extensive rewiring of epithelial-stromal co-expression networks in breast cancer. Genome Biology. 16: 128. PMID 26087699 DOI: 10.1186/S13059-015-0675-4 |
0.336 |
|
2015 |
Mui MZ, Zhou Y, Blanchette P, Chughtai N, Knight JF, Gruosso T, Papadakis AI, Huang S, Park M, Gingras AC, Branton PE. The human adenovirus type 5 E4orf4 protein targets two phosphatase regulators of the Hippo signaling pathway. Journal of Virology. PMID 26085163 DOI: 10.1128/Jvi.03710-14 |
0.445 |
|
2015 |
Yin J, Park G, Kim TH, Hong JH, Kim YJ, Jin X, Kang S, Jung JE, Kim JY, Yun H, Lee JE, Kim M, Chung J, Kim H, Nakano I, ... ... Park MJ, et al. Pigment Epithelium-Derived Factor (PEDF) Expression Induced by EGFRvIII Promotes Self-renewal and Tumor Progression of Glioma Stem Cells. Plos Biology. 13: e1002152. PMID 25992628 DOI: 10.1371/journal.pbio.1002152 |
0.315 |
|
2015 |
Li R, Knight JF, Park M, Pendergast AM. Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility. Plos One. 10: e0124960. PMID 25946048 DOI: 10.1371/Journal.Pone.0124960 |
0.601 |
|
2015 |
Tabariès S, Annis MG, Hsu BE, Tam CE, Savage P, Park M, Siegel PM. Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis. Oncotarget. 6: 9476-87. PMID 25823815 DOI: 10.18632/Oncotarget.3269 |
0.362 |
|
2015 |
You L, Yan K, Zou J, Zhao H, Bertos NR, Park M, Wang E, Yang XJ. The chromatin regulator Brpf1 regulates embryo development and cell proliferation. The Journal of Biological Chemistry. 290: 11349-64. PMID 25773539 DOI: 10.1074/Jbc.M115.643189 |
0.404 |
|
2015 |
You L, Yan K, Zhou J, Zhao H, Bertos NR, Park M, Wang E, Yang XJ. The lysine acetyltransferase activator Brpf1 governs dentate gyrus development through neural stem cells and progenitors. Plos Genetics. 11: e1005034. PMID 25757017 DOI: 10.1371/Journal.Pgen.1005034 |
0.334 |
|
2015 |
Ioannou MS, Bell ES, Girard M, Chaineau M, Hamlin JN, Daubaras M, Monast A, Park M, Hodgson L, McPherson PS. DENND2B activates Rab13 at the leading edge of migrating cells and promotes metastatic behavior. The Journal of Cell Biology. 208: 629-48. PMID 25713415 DOI: 10.1083/Jcb.201407068 |
0.357 |
|
2015 |
Havrylov S, Park M. MS/MS-based strategies for proteomic profiling of invasive cell structures. Proteomics. 15: 272-86. PMID 25303514 DOI: 10.1002/Pmic.201400220 |
0.357 |
|
2015 |
Gigoux M, Gruosso T, Bertos N, Saleh S, Omeroglu A, Zhao H, Souleimanova M, Meterissian S, Hallett M, Park M. Abstract A69: The immunological environment in triple negative breast cancer; impact on clinical outcomes towards a prognostic clinical test Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-A69 |
0.33 |
|
2015 |
Thompson C, Bertos N, Gruosso T, Finak G, Lesurf R, Saleh SM, Zhao H, Souleimanova M, Meterissian S, Omeroglu A, Hallett MT, Park M. Abstract P4-04-01: A new breast cancer classification scheme based on novel classes of tumor stroma Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-04-01 |
0.308 |
|
2015 |
Sangwan V, Jensen KM, Dudeja V, Chugh R, Banerjee S, Vickers SM, Park M, Saluja AK. Abstract B119: Triptolide abrogates expression of the Met and epidermal growth factor receptors in pancreatic cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-B119 |
0.454 |
|
2015 |
Saleh SM, Savage P, Laferrière J, Cory S, Bertos N, Souleimanova M, Zhao H, Zacksenhaus E, Muller W, Hallett M, Park M. Abstract A79: Mouse models of breast cancer identify oncogene-associated stroma subtypes Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-A79 |
0.348 |
|
2015 |
Frankenberger CA, Bainer RO, Rabe DC, Saleh S, Park M, Gilad Y, Rosner MR. Abstract A43: Systemic tumor-stroma interactions are prognostic indicators of breast tumor invasiveness Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-A43 |
0.325 |
|
2015 |
Gruosso T, Verteuil DAd, Saleh S, Lesurf R, Zhao H, Davis R, Zuo D, Cardiff R, Gregg J, Hallett M, Park M. Abstract LB-200: Loss of the scaffold protein Kibra in a mouse model of triple-negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-200 |
0.403 |
|
2015 |
Savage P, Saleh SM, Iacucci E, Revil T, Wang Y, Bertos N, Monast A, Zhao H, Souleimanova M, Szulwach K, Batchu C, Omeroglu A, Park M, Ragoussis I. Abstract LB-129: Identifying tumor subpopulations and the functional consequences of intratumor heterogeneity using single-cell profiling of breast cancer patient-derived xenografts Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-129 |
0.373 |
|
2015 |
Jiang H, Najmeh S, Berube J, Leone A, Savage P, Giannias B, Rousseau S, Park M, Ferri LE. Abstract 3162: NOD1 augments cancer cell metastatic potential through p38 MAP kinase activation Immunology. 75: 3162-3162. DOI: 10.1158/1538-7445.Am2015-3162 |
0.396 |
|
2014 |
Guo J, Canaff L, Rajadurai CV, Fils-Aimé N, Tian J, Dai M, Korah J, Villatoro M, Park M, Ali S, Lebrun JJ. Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes. Breast Cancer Research : Bcr. 16: 476. PMID 25499443 DOI: 10.1186/S13058-014-0476-9 |
0.372 |
|
2014 |
Vadnais C, Shooshtarizadeh P, Rajadurai CV, Lesurf R, Hulea L, Davoudi S, Cadieux C, Hallett M, Park M, Nepveu A. Autocrine Activation of the Wnt/β-Catenin Pathway by CUX1 and GLIS1 in Breast Cancers. Biology Open. 3: 937-46. PMID 25217618 DOI: 10.1242/Bio.20148193 |
0.382 |
|
2014 |
Hudson J, Ha JR, Sabourin V, Ahn R, La Selva R, Livingstone J, Podmore L, Knight J, Forrest L, Beauchemin N, Hallett M, Park M, Ursini-Siegel J. p66ShcA promotes breast cancer plasticity by inducing an epithelial-to-mesenchymal transition. Molecular and Cellular Biology. 34: 3689-701. PMID 25071152 DOI: 10.1128/Mcb.00341-14 |
0.367 |
|
2014 |
Lai AZ, Cory S, Zhao H, Gigoux M, Monast A, Guiot MC, Huang S, Tofigh A, Thompson C, Naujokas M, Marcus VA, Bertos N, Sehat B, Perera RM, Bell ES, ... ... Park M, et al. Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer. Science Signaling. 7: ra38. PMID 24757178 DOI: 10.1126/Scisignal.2004839 |
0.499 |
|
2014 |
Stern YE, Lai AZ, Park M. Abstract LB-77: The Met receptor tyrosine kinase drives signaling through EGFR and ErbB3 in Met-amplified non-small-cell lung cancer Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-77 |
0.549 |
|
2014 |
Bell ES, Zuo D, Park M. Abstract 3453: Autophagic regulation of the Met receptor tyrosine kinase in breast cancer Cancer Research. 74: 3453-3453. DOI: 10.1158/1538-7445.Am2014-3453 |
0.543 |
|
2013 |
Wallace JA, Li F, Balakrishnan S, Cantemir-Stone CZ, Pecot T, Martin C, Kladney RD, Sharma SM, Trimboli AJ, Fernandez SA, Yu L, Rosol TJ, Stromberg PC, Lesurf R, Hallett M, ... Park M, et al. Ets2 in tumor fibroblasts promotes angiogenesis in breast cancer. Plos One. 8: e71533. PMID 23977064 DOI: 10.1371/Journal.Pone.0071533 |
0.365 |
|
2013 |
Ahn R, Sabourin V, Ha JR, Cory S, Maric G, Im YK, Hardy WR, Zhao H, Park M, Hallett M, Siegel PM, Pawson T, Ursini-Siegel J. The ShcA PTB domain functions as a biological sensor of phosphotyrosine signaling during breast cancer progression. Cancer Research. 73: 4521-32. PMID 23695548 DOI: 10.1158/0008-5472.Can-12-4178 |
0.525 |
|
2013 |
Laurin M, Huber J, Pelletier A, Houalla T, Park M, Fukui Y, Haibe-Kains B, Muller WJ, Côté JF. Rac-specific guanine nucleotide exchange factor DOCK1 is a critical regulator of HER2-mediated breast cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America. 110: 7434-9. PMID 23592719 DOI: 10.1073/Pnas.1213050110 |
0.465 |
|
2013 |
Ursini-Siegel J, Park M. It takes two to tango in the microenvironment! Breast Cancer Research : Bcr. 15: 102. PMID 23510134 DOI: 10.1186/Bcr3388 |
0.415 |
|
2013 |
Knight JF, Lesurf R, Zhao H, Pinnaduwage D, Davis RR, Saleh SM, Zuo D, Naujokas MA, Chughtai N, Herschkowitz JI, Prat A, Mulligan AM, Muller WJ, Cardiff RD, Gregg JP, ... ... Park M, et al. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 110: E1301-10. PMID 23509284 DOI: 10.1073/Pnas.1210353110 |
0.409 |
|
2013 |
Knight JF, Lesurf R, Saleh SM, Davis RR, Zhao H, Zuo D, Cardiff RD, Gregg J, Hallett M, Park M. Abstract PR01: Loss of the hippo pathway scaffold “Kibra” in a mouse model of human claudin-low breast cancer Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-Pr01 |
0.447 |
|
2013 |
Sung V, Knight JF, Park M. Abstract B009: A role for receptor tyrosine kinase crosstalk in a Met-dependent model of triple-negative breast cancer Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-B009 |
0.437 |
|
2013 |
Lai AZ, Thompson C, Cory S, Zhao H, Chughtai N, Hallett M, Park M. Abstract 967: Establishing mechanisms of acquired resistance to Met inhibitor in Met-addicted gastric cancer cell lines. Cancer Research. 73: 967-967. DOI: 10.1158/1538-7445.Am2013-967 |
0.476 |
|
2013 |
Sung VYC, Knight JF, Park M. Abstract 265: Mechanisms of Met-dependent tumorigenesis in models of triple negative breast cancer. Cancer Research. 73: 265-265. DOI: 10.1158/1538-7445.Am2013-265 |
0.415 |
|
2013 |
Lai A, Cory S, Zhao H, Sehat B, Tofigh A, Guiot M, Thompson C, Bell ES, Bertos N, Ferri LE, Hallett M, Park M. Abstract B69: Dynamic reprogramming of signaling following Met inhibition reveals pathways for cell proliferation and negative feedback in gastric cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B69 |
0.466 |
|
2012 |
Bell ES, Park M. Models of crk adaptor proteins in cancer. Genes & Cancer. 3: 341-52. PMID 23226572 DOI: 10.1177/1947601912459951 |
0.455 |
|
2012 |
Mourskaia AA, Amir E, Dong Z, Tiedemann K, Cory S, Omeroglu A, Bertos N, Ouellet V, Clemons M, Scheffer GL, Park M, Hallett M, Komarova SV, Siegel PM. ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. Breast Cancer Research : Bcr. 14: R149. PMID 23174366 DOI: 10.1186/Bcr3361 |
0.301 |
|
2012 |
Pepin F, Bertos N, Laferrière J, Sadekova S, Souleimanova M, Zhao H, Finak G, Meterissian S, Hallett MT, Park M. Gene-expression profiling of microdissected breast cancer microvasculature identifies distinct tumor vascular subtypes. Breast Cancer Research : Bcr. 14: R120. PMID 22906178 DOI: 10.1186/Bcr3246 |
0.316 |
|
2012 |
Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA, Park M, Bergers G. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell. 22: 21-35. PMID 22789536 DOI: 10.1016/J.Ccr.2012.05.037 |
0.785 |
|
2012 |
Fathers KE, Bell ES, Rajadurai CV, Cory S, Zhao H, Mourskaia A, Zuo D, Madore J, Monast A, Mes-Masson AM, Grosset AA, Gaboury L, Hallet M, Siegel P, Park M. Crk adaptor proteins act as key signaling integrators for breast tumorigenesis. Breast Cancer Research : Bcr. 14: R74. PMID 22569336 DOI: 10.1186/Bcr3183 |
0.436 |
|
2012 |
Garbe JC, Pepin F, Pelissier FA, Sputova K, Fridriksdottir AJ, Guo DE, Villadsen R, Park M, Petersen OW, Borowsky AD, Stampfer MR, Labarge MA. Accumulation of multipotent progenitors with a basal differentiation bias during aging of human mammary epithelia. Cancer Research. 72: 3687-701. PMID 22552289 DOI: 10.1158/0008-5472.Can-12-0157 |
0.347 |
|
2012 |
Wang Y, Roche O, Xu C, Moriyama EH, Heir P, Chung J, Roos FC, Chen Y, Finak G, Milosevic M, Wilson BC, Teh BT, Park M, Irwin MS, Ohh M. Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1. Proceedings of the National Academy of Sciences of the United States of America. 109: 4892-7. PMID 22411794 DOI: 10.1073/Pnas.1112129109 |
0.496 |
|
2012 |
Parachoniak CA, Park M. Dynamics of receptor trafficking in tumorigenicity. Trends in Cell Biology. 22: 231-40. PMID 22397948 DOI: 10.1016/J.Tcb.2012.02.002 |
0.803 |
|
2012 |
Rajadurai CV, Havrylov S, Zaoui K, Vaillancourt R, Stuible M, Naujokas M, Zuo D, Tremblay ML, Park M. Met receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodia. Journal of Cell Science. 125: 2940-53. PMID 22366451 DOI: 10.1242/Jcs.100834 |
0.612 |
|
2012 |
Lai AZ, Durrant M, Zuo D, Ratcliffe CD, Park M. Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer. The Journal of Biological Chemistry. 287: 8048-59. PMID 22262855 DOI: 10.1074/Jbc.M112.339820 |
0.539 |
|
2012 |
Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H, Srinivasan R, Trimboli AJ, Martin CK, Li F, Yu L, Fernandez SA, Pécot T, Rosol TJ, Cory S, ... ... Park M, et al. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nature Cell Biology. 14: 159-67. PMID 22179046 DOI: 10.1038/Ncb2396 |
0.33 |
|
2012 |
Lai AZ, Zhao H, Cory S, Bell ES, Hallett M, Park M. Abstract 1222: Met-dependent positive and negative signaling cascades in gastric cancer cells Cancer Research. 72: 1222-1222. DOI: 10.1158/1538-7445.Am2012-1222 |
0.34 |
|
2012 |
Lai AZ, Cory S, Zhao H, Bell ES, Hallett M, Park M. Abstract B45: Met-Dependent Positive and Negative Signaling Cascades in Gastric Cancer Cells Clinical Cancer Research. 18: B45-B45. DOI: 10.1158/1078-0432.Mechres-B45 |
0.524 |
|
2012 |
Bertos N, Finak G, Lesurf R, Saleh S, Zhao H, Souleimanova M, Meterrisian S, Omeroglu A, Hallett M, Park M. Abstract ES8-2: Breast Cancer Stroma: A Predictor of Clinical Outcome and Tumour Heterogeneity Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-Es8-2 |
0.312 |
|
2011 |
Sangwan V, Abella J, Lai A, Bertos N, Stuible M, Tremblay ML, Park M. Protein-tyrosine phosphatase 1B modulates early endosome fusion and trafficking of Met and epidermal growth factor receptors. The Journal of Biological Chemistry. 286: 45000-13. PMID 22045810 DOI: 10.1074/Jbc.M111.270934 |
0.547 |
|
2011 |
Parachoniak CA, Luo Y, Abella JV, Keen JH, Park M. GGA3 functions as a switch to promote Met receptor recycling, essential for sustained ERK and cell migration. Developmental Cell. 20: 751-63. PMID 21664574 DOI: 10.1016/J.Devcel.2011.05.007 |
0.84 |
|
2011 |
Liu X, Nugoli M, Laferrière J, Saleh SM, Rodrigue-Gervais IG, Saleh M, Park M, Hallett MT, Muller WJ, Giguère V. Stromal retinoic acid receptor beta promotes mammary gland tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 108: 774-9. PMID 21187396 DOI: 10.1073/Pnas.1011845108 |
0.429 |
|
2011 |
Tabariès S, Dong Z, Annis MG, Omeroglu A, Pepin F, Ouellet V, Russo C, Hassanain M, Metrakos P, Diaz Z, Basik M, Bertos N, Park M, Guettier C, Adam R, et al. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene. 30: 1318-28. PMID 21076473 DOI: 10.1038/Onc.2010.518 |
0.347 |
|
2011 |
Hanson ES, Fathers KE, Rajadurai CV, Monast A, Cory S, Zhao H, Zuo D, Grosset A, Gaboury L, Madore J, Hallett M, Siegel P, Park M. Abstract 918: A key role for Crk adaptor proteins in basal breast cancer tumor growth in vivo Cancer Research. 71: 918-918. DOI: 10.1158/1538-7445.Am2011-918 |
0.435 |
|
2011 |
Lai A, Park M. Abstract 4688: Met receptor tyrosine kinase cross-talk in tumorigenesis Cancer Research. 71: 4688-4688. DOI: 10.1158/1538-7445.Am2011-4688 |
0.587 |
|
2011 |
Mihalcioiu C, Lian J, Bertos N, Omeroglu A, Sebag M, DiBattista J, Li J, Chughtai N, Park M, Kremer R. P4-07-02: Detection, Enrichment, Characterization and Propagation of Circulating Tumour Cells from Patients with Advanced Metastatic Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P4-07-02 |
0.311 |
|
2010 |
Myhre S, Mohammed H, Tramm T, Alsner J, Finak G, Park M, Overgaard J, Børresen-Dale AL, Frigessi A, Sørlie T. In silico ascription of gene expression differences to tumor and stromal cells in a model to study impact on breast cancer outcome. Plos One. 5: e14002. PMID 21124964 DOI: 10.1371/Journal.Pone.0014002 |
0.334 |
|
2010 |
Ursini-Siegel J, Cory S, Zuo D, Hardy WR, Rexhepaj E, Lam S, Schade B, Jirstrom K, Bjur E, Piccirillo CA, Denardo D, Coussens LM, Brennan DJ, Gallagher WM, Park M, et al. Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response. Cancer Research. 70: 7776-87. PMID 20924104 DOI: 10.1158/0008-5472.Can-10-2229 |
0.455 |
|
2010 |
Eichner LJ, Perry MC, Dufour CR, Bertos N, Park M, St-Pierre J, Giguère V. miR-378(∗) mediates metabolic shift in breast cancer cells via the PGC-1β/ERRγ transcriptional pathway. Cell Metabolism. 12: 352-61. PMID 20889127 DOI: 10.1016/J.Cmet.2010.09.002 |
0.309 |
|
2010 |
Hardy S, Wong NN, Muller WJ, Park M, Tremblay ML. Overexpression of the protein tyrosine phosphatase PRL-2 correlates with breast tumor formation and progression. Cancer Research. 70: 8959-67. PMID 20841483 DOI: 10.1158/0008-5472.Can-10-2041 |
0.436 |
|
2010 |
Rose AA, Annis MG, Dong Z, Pepin F, Hallett M, Park M, Siegel PM. ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties. Plos One. 5: e12093. PMID 20711474 DOI: 10.1371/Journal.Pone.0012093 |
0.386 |
|
2010 |
Abella JV, Parachoniak CA, Sangwan V, Park M. Dorsal ruffle microdomains potentiate Met receptor tyrosine kinase signaling and down-regulation. The Journal of Biological Chemistry. 285: 24956-67. PMID 20529867 DOI: 10.1074/Jbc.M110.127985 |
0.826 |
|
2010 |
Stuible M, Abella JV, Feldhammer M, Nossov M, Sangwan V, Blagoev B, Park M, Tremblay ML. PTP1B targets the endosomal sorting machinery: dephosphorylation of regulatory sites on the endosomal sorting complex required for transport component STAM2. The Journal of Biological Chemistry. 285: 23899-907. PMID 20504764 DOI: 10.1074/Jbc.M110.115295 |
0.56 |
|
2010 |
Abella JV, Vaillancourt R, Frigault MM, Ponzo MG, Zuo D, Sangwan V, Larose L, Park M. The Gab1 scaffold regulates RTK-dependent dorsal ruffle formation through the adaptor Nck. Journal of Cell Science. 123: 1306-19. PMID 20332103 DOI: 10.1242/Jcs.062570 |
0.487 |
|
2010 |
Ponzo MG, Park M. The Met receptor tyrosine kinase and basal breast cancer. Cell Cycle (Georgetown, Tex.). 9: 1043-50. PMID 20237428 DOI: 10.4161/Cc.9.6.11033 |
0.426 |
|
2010 |
Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M, Gaboury L, Siegel PM. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2147-56. PMID 20215530 DOI: 10.1158/1078-0432.Ccr-09-1611 |
0.311 |
|
2010 |
Fathers KE, Rodrigues S, Zuo D, Murthy IV, Hallett M, Cardiff R, Park M. CrkII transgene induces atypical mammary gland development and tumorigenesis. The American Journal of Pathology. 176: 446-60. PMID 20008144 DOI: 10.2353/Ajpath.2010.090383 |
0.373 |
|
2010 |
Rose A, Grosset A, Dong Z, Bertos N, Simantov R, Park M, Gaboury L, Siegel P. Abstract A8: GPNMB is an independent prognostic indicator of recurrence and a therapeutic target in triple negative breast cancer Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcme10-A8 |
0.317 |
|
2010 |
Rose A, Annis M, Dong Z, Pepin F, Hallett M, Park M, Siegel P. Abstract P1-02-02: Processing of GPNMB by ADAM-10 in Breast Tumors Releases an Extracellular Domain with Angiogenic Properties Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P1-02-02 |
0.4 |
|
2009 |
Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N, Thompson JC, Caserta E, Wang H, Chong JL, Naidu S, Wei G, Sharma SM, Stephens JA, Fernandez SA, ... ... Park M, et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature. 461: 1084-91. PMID 19847259 DOI: 10.1038/Nature08486 |
0.419 |
|
2009 |
Lai AZ, Abella JV, Park M. Crosstalk in Met receptor oncogenesis. Trends in Cell Biology. 19: 542-51. PMID 19758803 DOI: 10.1016/J.Tcb.2009.07.002 |
0.533 |
|
2009 |
Kedinger V, Sansregret L, Harada R, Vadnais C, Cadieux C, Fathers K, Park M, Nepveu A. p110 CUX1 homeodomain protein stimulates cell migration and invasion in part through a regulatory cascade culminating in the repression of E-cadherin and occludin. The Journal of Biological Chemistry. 284: 27701-11. PMID 19635798 DOI: 10.1074/Jbc.M109.031849 |
0.409 |
|
2009 |
Deblois G, Hall JA, Perry MC, Laganière J, Ghahremani M, Park M, Hallett M, Giguère V. Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity. Cancer Research. 69: 6149-57. PMID 19622763 DOI: 10.1158/0008-5472.Can-09-1251 |
0.401 |
|
2009 |
Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, Germain D, Omeroglu A, Cardiff RD, Hallett M, Park M. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 106: 12903-8. PMID 19617568 DOI: 10.1073/Pnas.0810402106 |
0.399 |
|
2009 |
Paliouras GN, Naujokas MA, Park M. Pak4, a novel Gab1 binding partner, modulates cell migration and invasion by the Met receptor. Molecular and Cellular Biology. 29: 3018-32. PMID 19289496 DOI: 10.1128/Mcb.01286-08 |
0.587 |
|
2009 |
Wang Y, Roche O, Yan MS, Finak G, Evans AJ, Metcalf JL, Hast BE, Hanna SC, Wondergem B, Furge KA, Irwin MS, Kim WY, Teh BT, Grinstein S, Park M, et al. Regulation of endocytosis via the oxygen-sensing pathway. Nature Medicine. 15: 319-24. PMID 19252501 DOI: 10.1038/Nm.1922 |
0.492 |
|
2009 |
Abella JV, Park M. Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. American Journal of Physiology. Endocrinology and Metabolism. 296: E973-84. PMID 19240253 DOI: 10.1152/Ajpendo.90857.2008 |
0.533 |
|
2009 |
Parachoniak CA, Park M. Distinct recruitment of Eps15 via Its coiled-coil domain is required for efficient down-regulation of the met receptor tyrosine kinase. The Journal of Biological Chemistry. 284: 8382-94. PMID 19109251 DOI: 10.1074/Jbc.M807607200 |
0.835 |
|
2008 |
Sangwan V, Paliouras GN, Abella JV, Dubé N, Monast A, Tremblay ML, Park M. Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase. The Journal of Biological Chemistry. 283: 34374-83. PMID 18819921 DOI: 10.1074/Jbc.M805916200 |
0.577 |
|
2008 |
Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M. Stromal gene expression predicts clinical outcome in breast cancer. Nature Medicine. 14: 518-27. PMID 18438415 DOI: 10.1038/Nm1764 |
0.301 |
|
2008 |
Frigault MM, Naujokas MA, Park M. Gab2 requires membrane targeting and the Met binding motif to promote lamellipodia, cell scatter, and epithelial morphogenesis downstream from the Met receptor. Journal of Cellular Physiology. 214: 694-705. PMID 17894413 DOI: 10.1002/Jcp.21264 |
0.522 |
|
2007 |
Kozlov G, Nguyen L, Lin T, De Crescenzo G, Park M, Gehring K. Structural basis of ubiquitin recognition by the ubiquitin-associated (UBA) domain of the ubiquitin ligase EDD. The Journal of Biological Chemistry. 282: 35787-95. PMID 17897937 DOI: 10.1074/Jbc.M705655200 |
0.342 |
|
2007 |
Peschard P, Kozlov G, Lin T, Mirza IA, Berghuis AM, Lipkowitz S, Park M, Gehring K. Structural basis for ubiquitin-mediated dimerization and activation of the ubiquitin protein ligase Cbl-b. Molecular Cell. 27: 474-85. PMID 17679095 DOI: 10.1016/J.Molcel.2007.06.023 |
0.421 |
|
2007 |
Kozlov G, Peschard P, Zimmerman B, Lin T, Moldoveanu T, Mansur-Azzam N, Gehring K, Park M. Structural basis for UBA-mediated dimerization of c-Cbl ubiquitin ligase. The Journal of Biological Chemistry. 282: 27547-55. PMID 17635922 DOI: 10.1074/Jbc.M703333200 |
0.475 |
|
2007 |
Mak HHL, Peschard P, Lin T, Naujokas MA, Zuo D, Park M. Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway Oncogene. 26: 7213-7221. PMID 17533376 DOI: 10.1038/Sj.Onc.1210522 |
0.522 |
|
2007 |
Peschard P, Park M. From Tpr-Met to Met, tumorigenesis and tubes Oncogene. 26: 1276-1285. PMID 17322912 DOI: 10.1038/Sj.Onc.1210201 |
0.543 |
|
2006 |
Mood K, Saucier C, Bong YS, Lee HS, Park M, Daar IO. Gab1 is required for cell cycle transition, cell proliferation, and transformation induced by an oncogenic met receptor. Molecular Biology of the Cell. 17: 3717-28. PMID 16775003 DOI: 10.1091/Mbc.E06-03-0244 |
0.745 |
|
2006 |
Mood K, Saucier C, Ishimura A, Bong YS, Lee HS, Park M, Daar IO. Oncogenic Met receptor induces cell-cycle progression in Xenopus oocytes independent of direct Grb2 and Shc binding or Mos synthesis, but requires phosphatidylinositol 3-kinase and Raf signaling. Journal of Cellular Physiology. 207: 271-85. PMID 16331688 DOI: 10.1002/Jcp.20564 |
0.767 |
|
2006 |
Sangwan V, Paliouras GN, Cheng A, Dubé N, Tremblay ML, Park M. Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure. The Journal of Biological Chemistry. 281: 221-8. PMID 16234234 DOI: 10.1074/Jbc.M507858200 |
0.382 |
|
2006 |
Sangwan V, Park M. Receptor tyrosine kinases: Role in cancer progression Current Oncology. 13: 191-193. |
0.38 |
|
2005 |
Suzuki M, Mimuro H, Suzuki T, Park M, Yamamoto T, Sasakawa C. Interaction of CagA with Crk plays an important role in Helicobacter pylori-induced loss of gastric epithelial cell adhesion. The Journal of Experimental Medicine. 202: 1235-47. PMID 16275761 DOI: 10.1084/Jem.20051027 |
0.381 |
|
2005 |
Abella JV, Peschard P, Naujokas MA, Lin T, Saucier C, Urbé S, Park M. Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Molecular and Cellular Biology. 25: 9632-45. PMID 16227611 DOI: 10.1128/Mcb.25.21.9632-9645.2005 |
0.743 |
|
2005 |
Kim H, Chan R, Dankort DL, Zuo D, Najoukas M, Park M, Muller WJ. The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation. Oncogene. 24: 7599-607. PMID 16170374 DOI: 10.1038/Sj.Onc.1208898 |
0.543 |
|
2005 |
Long J, Zuo D, Park M. Pc2-mediated sumoylation of Smad-interacting protein 1 attenuates transcriptional repression of E-cadherin. The Journal of Biological Chemistry. 280: 35477-89. PMID 16061479 DOI: 10.1074/Jbc.M504477200 |
0.405 |
|
2005 |
Rodrigues SP, Fathers KE, Chan G, Zuo D, Halwani F, Meterissian S, Park M. CrkI and CrkII function as key signaling integrators for migration and invasion of cancer cells. Molecular Cancer Research : McR. 3: 183-94. PMID 15831672 DOI: 10.1158/1541-7786.Mcr-04-0211 |
0.434 |
|
2005 |
Khoury H, Naujokas MA, Zuo D, Sangwan V, Frigault MM, Petkiewicz S, Dankort DL, Muller WJ, Park M. HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Molecular Biology of the Cell. 16: 550-61. PMID 15548598 DOI: 10.1091/Mbc.E04-07-0567 |
0.746 |
|
2004 |
Kozlov G, Perreault A, Schrag JD, Park M, Cygler M, Gehring K, Ekiel I. Insights into function of PSI domains from structure of the Met receptor PSI domain. Biochemical and Biophysical Research Communications. 321: 234-40. PMID 15358240 DOI: 10.1016/J.Bbrc.2004.06.132 |
0.411 |
|
2004 |
Peschard P, Ishiyama N, Lin T, Lipkowitz S, Park M. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. The Journal of Biological Chemistry. 279: 29565-71. PMID 15123609 DOI: 10.1074/Jbc.M403954200 |
0.479 |
|
2004 |
Saucier C, Khoury H, Lai KM, Peschard P, Dankort D, Naujokas MA, Holash J, Yancopoulos GD, Muller WJ, Pawson T, Park M. The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. 101: 2345-50. PMID 14983012 DOI: 10.1073/Pnas.0308065101 |
0.765 |
|
2004 |
Chan G, Rodrigues SP, Halwani F, Meterissian S, Park M. The suppression of Crk inhibits the metastatic profile of breast cancer cells lines Annals of Surgical Oncology. 11. DOI: 10.1007/Bf02524078 |
0.439 |
|
2003 |
Lamorte L, Park M. ARF1 and ARF6 are dispensable for Crk-dependent epithelial-mesenchymal-like transitions. Anticancer Research. 23: 2085-92. PMID 12894582 |
0.812 |
|
2003 |
Lamorte L, Rodrigues S, Sangwan V, Turner CE, Park M. Crk associates with a multimolecular Paxillin/GIT2/beta-PIX complex and promotes Rac-dependent relocalization of Paxillin to focal contacts. Molecular Biology of the Cell. 14: 2818-31. PMID 12857867 DOI: 10.1091/Mbc.E02-08-0497 |
0.79 |
|
2003 |
Peschard P, Park M. Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell. 3: 519-23. PMID 12842080 DOI: 10.1016/S1535-6108(03)00136-3 |
0.523 |
|
2003 |
Lock LS, Frigault MM, Saucier C, Park M. Grb2-independent recruitment of Gab1 requires the C-terminal lobe and structural integrity of the Met receptor kinase domain. The Journal of Biological Chemistry. 278: 30083-90. PMID 12766170 DOI: 10.1074/Jbc.M302675200 |
0.822 |
|
2003 |
Maroun CR, Naujokas MA, Park M. Membrane targeting of Grb2-associated binder-1 (Gab1) scaffolding protein through Src myristoylation sequence substitutes for Gab1 pleckstrin homology domain and switches an epidermal growth factor response to an invasive morphogenic program. Molecular Biology of the Cell. 14: 1691-708. PMID 12686619 DOI: 10.1091/Mbc.E02-06-0352 |
0.513 |
|
2003 |
Palka HL, Park M, Tonks NK. Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. The Journal of Biological Chemistry. 278: 5728-35. PMID 12475979 DOI: 10.1074/Jbc.M210656200 |
0.525 |
|
2002 |
Lamorte L, Rodrigues S, Naujokas M, Park M. Crk synergizes with epidermal growth factor for epithelial invasion and morphogenesis and is required for the met morphogenic program. The Journal of Biological Chemistry. 277: 37904-11. PMID 12138161 DOI: 10.1074/Jbc.M201743200 |
0.82 |
|
2002 |
Lock LS, Maroun CR, Naujokas MA, Park M. Distinct recruitment and function of Gab1 and Gab2 in Met receptor-mediated epithelial morphogenesis. Molecular Biology of the Cell. 13: 2132-46. PMID 12058075 DOI: 10.1091/Mbc.02-02-0031 |
0.85 |
|
2002 |
Lamorte L, Royal I, Naujokas M, Park M. Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions. Molecular Biology of the Cell. 13: 1449-61. PMID 12006644 DOI: 10.1091/Mbc.01-10-0477 |
0.847 |
|
2002 |
Saucier C, Papavasiliou V, Palazzo A, Naujokas MA, Kremer R, Park M. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis. Oncogene. 21: 1800-11. PMID 11896612 DOI: 10.1038/Sj.Onc.1205261 |
0.836 |
|
2001 |
Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, Langdon WY, Park M. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Molecular Cell. 8: 995-1004. PMID 11741535 DOI: 10.1016/S1097-2765(01)00378-1 |
0.816 |
|
2001 |
Lamorte L, Park M. The receptor tyrosine kinases: role in cancer progression. Surgical Oncology Clinics of North America. 10: 271-88, viii. PMID 11382587 DOI: 10.1016/S1055-3207(18)30065-6 |
0.822 |
|
2001 |
Khoury H, Dankort DL, Sadekova S, Naujokas MA, Muller WJ, Park M. Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor. Oncogene. 20: 788-99. PMID 11314013 DOI: 10.1038/Sj.Onc.1204166 |
0.729 |
|
2000 |
Lamorte L, Kamikura DM, Park M. A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein. Oncogene. 19: 5973-81. PMID 11146548 DOI: 10.1038/Sj.Onc.1203977 |
0.821 |
|
2000 |
Shen Y, Naujokas M, Park M, Ireton K. InIB-dependent internalization of Listeria is mediated by the Met receptor tyrosine kinase. Cell. 103: 501-10. PMID 11081636 DOI: 10.1016/S0092-8674(00)00141-0 |
0.578 |
|
2000 |
Maroun CR, Naujokas MA, Holgado-Madruga M, Wong AJ, Park M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Molecular and Cellular Biology. 20: 8513-8525. PMID 11046147 DOI: 10.1128/Mcb.20.22.8513-8525.2000 |
0.595 |
|
2000 |
Fournier TM, Lamorte L, Maroun CR, Lupher M, Band H, Langdon W, Park M. Cbl-transforming variants trigger a cascade of molecular alterations that lead to epithelial mesenchymal conversion. Molecular Biology of the Cell. 11: 3397-410. PMID 11029044 DOI: 10.1091/Mbc.11.10.3397 |
0.819 |
|
2000 |
Lock LS, Royal I, Naujokas MA, Park M. Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab1 to receptor tyrosine kinases. The Journal of Biological Chemistry. 275: 31536-45. PMID 10913131 DOI: 10.1074/Jbc.M003597200 |
0.816 |
|
2000 |
Royal I, Lamarche-Vane N, Lamorte L, Kaibuchi K, Park M. Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. Molecular Biology of the Cell. 11: 1709-25. PMID 10793146 DOI: 10.1091/Mbc.11.5.1709 |
0.839 |
|
2000 |
Kamikura DM, Khoury H, Maroun C, Naujokas MA, Park M. Enhanced transformation by a plasma membrane-associated met oncoprotein: activation of a phosphoinositide 3'-kinase-dependent autocrine loop involving hyaluronic acid and CD44. Molecular and Cellular Biology. 20: 3482-96. PMID 10779338 DOI: 10.1128/Mcb.20.10.3482-3496.2000 |
0.691 |
|
2000 |
Shi ZQ, Yu DH, Park M, Marshall M, Feng GS. Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity. Molecular and Cellular Biology. 20: 1526-36. PMID 10669730 DOI: 10.1128/Mcb.20.5.1526-1536.2000 |
0.491 |
|
1999 |
Maroun CR, Moscatello DK, Naujokas MA, Holgado-Madruga M, Wong AJ, Park M. A conserved inositol phospholipid binding site within the pleckstrin homology domain of the Gab1 docking protein is required for epithelial morphogenesis. Journal of Biological Chemistry. 274: 31719-31726. PMID 10531383 DOI: 10.1074/Jbc.274.44.31719 |
0.547 |
|
1999 |
Maroun CR, Holgado-Madruga M, Royal I, Naujokas MA, Fournier TM, Wong AJ, Park M. The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Molecular and Cellular Biology. 19: 1784-99. PMID 10022866 DOI: 10.1128/Mcb.19.3.1784 |
0.846 |
|
1998 |
Tsao M, Liu N, Chen J, Pappas J, Ho J, To C, Viallet J, Park M, Zhu H. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers Lung Cancer. 20: 1-16. PMID 9699182 DOI: 10.1016/S0169-5002(98)00007-5 |
0.434 |
|
1998 |
Lin JC, Naujokas M, Zhu H, Nolet S, Park M. Intron-exon structure of the MET gene and cloning of an alternatively-spliced Met isoform reveals frequent exon-skipping of a single large internal exon. Oncogene. 16: 833-42. PMID 9484774 DOI: 10.1038/Sj.Onc.1201599 |
0.475 |
|
1997 |
Royal I, Fournier TM, Park M. Differential requirement of Grb2 and PI3-kinase in HGF/SF-induced cell motility and tubulogenesis. Journal of Cellular Physiology. 173: 196-201. PMID 9365521 DOI: 10.1002/(Sici)1097-4652(199711)173:2<196::Aid-Jcp20>3.0.Co;2-D |
0.843 |
|
1997 |
Nguyen L, Holgado-Madruga M, Maroun C, Fixman ED, Kamikura D, Fournier T, Charest A, Tremblay ML, Wong AJ, Park M. Association of the multisubstrate docking protein Gab1 with the hepatocyte growth factor receptor requires a functional Grb2 binding site involving tyrosine 1356 Journal of Biological Chemistry. 272: 20811-20819. PMID 9252406 DOI: 10.1074/Jbc.272.33.20811 |
0.856 |
|
1997 |
Fixman ED, Holgado-Madruga M, Nguyen L, Kamikura DM, Fournier TM, Wong AJ, Park M. Efficient cellular transformation by the Met oncoprotein requires a functional Grb2 binding site and correlates with phosphorylation of the Grb2-associated proteins, Cbl and Gab1. The Journal of Biological Chemistry. 272: 20167-72. PMID 9242692 DOI: 10.1074/Jbc.272.32.20167 |
0.844 |
|
1997 |
Rodrigues GA, Park M, Schlessinger J. Activation of the JNK pathway is essential for transformation by the Met oncogene. The Embo Journal. 16: 2634-45. PMID 9184210 DOI: 10.1093/Emboj/16.10.2634 |
0.542 |
|
1997 |
Jin L, Fuchs A, Schnitt SJ, Yao Y, Joseph A, Lamszus K, Park M, Goldberg ID, Rosen EM. Expression of scatter factor and c-met receptor in benign and malignant breast tissue Cancer. 79: 749-760. PMID 9024713 DOI: 10.1002/(Sici)1097-0142(19970215)79:4<749::Aid-Cncr12>3.0.Co;2-# |
0.402 |
|
1996 |
Aklilu F, Park M, Goltzman D, Rabbani SA. Increased PTHRP production by a tyrosine kinase oncogene, Tpr-Met: role of the Ras signaling pathway. The American Journal of Physiology. 271: E277-83. PMID 8770021 DOI: 10.1152/Ajpendo.1996.271.2.E277 |
0.493 |
|
1996 |
Fournier TM, Kamikura D, Teng K, Park M. Branching tubulogenesis but not scatter of madin-darby canine kidney cells requires a functional Grb2 binding site in the Met receptor tyrosine kinase. The Journal of Biological Chemistry. 271: 22211-7. PMID 8703035 DOI: 10.1074/Jbc.271.36.22211 |
0.853 |
|
1996 |
Fixman ED, Fournier TM, Kamikura DM, Naujokas MA, Park M. Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein. The Journal of Biological Chemistry. 271: 13116-22. PMID 8662733 DOI: 10.1074/Jbc.271.22.13116 |
0.838 |
|
1996 |
Kamikura DM, Naujokas MA, Park M. Identification of tyrosine 489 in the carboxy terminus of the Tpr-Met oncoprotein as a major site of autophosphorylation. Biochemistry. 35: 1010-7. PMID 8547236 DOI: 10.1021/Bi9514065 |
0.555 |
|
1995 |
Byers S, Park M, Sommers C, Seslar S. Breast carcinoma: a collective disorder. Breast Cancer Research and Treatment. 31: 203-15. PMID 7533561 DOI: 10.1007/Bf00666154 |
0.467 |
|
1995 |
Royal I, Park M. Hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells requires phosphatidylinositol 3-kinase. The Journal of Biological Chemistry. 270: 27780-7. PMID 7499247 DOI: 10.1074/Jbc.270.46.27780 |
0.81 |
|
1994 |
Santos OFP, Barros EJG, Yang XM, Matsumoto K, Nakamura T, Park M, Nigam SK. Involvement of hepatocyte growth factor in kidney development Developmental Biology. 163: 525-529. PMID 8200486 DOI: 10.1006/Dbio.1994.1169 |
0.346 |
|
1994 |
Rodrigues GA, Park M. Oncogenic activation of tyrosine kinases. Current Opinion in Genetics & Development. 4: 15-24. PMID 8193535 DOI: 10.1016/0959-437X(94)90086-8 |
0.498 |
|
1994 |
Naidu YM, Rosen EM, Zitnick R, Goldberg I, Park M, Naujokas M, Polverini PJ, Nickoloff BJ. Role of scatter factor in the pathogenesis of AIDS-related Kaposi sarcoma Proceedings of the National Academy of Sciences of the United States of America. 91: 5281-5285. PMID 7515495 DOI: 10.1073/Pnas.91.12.5281 |
0.415 |
|
1993 |
Rodrigues GA, Park M. Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Molecular and Cellular Biology. 13: 6711-22. PMID 8413267 DOI: 10.1128/Mcb.13.11.6711 |
0.547 |
|
1993 |
Yang X, Park M. Expression of the met/hepatocyte growth factor/scatter factor receptor and its ligand during differentiation of murine P19 embryonal carcinoma cells. Developmental Biology. 157: 308-320. PMID 8388815 DOI: 10.1006/Dbio.1993.1137 |
0.468 |
|
1992 |
Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K, Park M, Chan A, Aaronson S, Vande Woude GF. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Molecular and Cellular Biology. 12: 5152-8. PMID 1406687 DOI: 10.1128/Mcb.12.11.5152 |
0.497 |
|
1988 |
Gonzatti-Haces M, Seth A, Park M, Copeland T, Oroszlan S, Vande Woude GF. Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proceedings of the National Academy of Sciences of the United States of America. 85: 21-5. PMID 3277171 DOI: 10.1073/Pnas.85.1.21 |
0.515 |
|
1987 |
Park M, Gonzatti-Haces M, Dean M, Blair DG, Testa JR, Bennett DD, Copeland T, Oroszlan S, Vande Woude G. The met oncogene: a new member of the tyrosine kinase family and a marker for cystic fibrosis. Cold Spring Harbor Symposia On Quantitative Biology. 967-75. PMID 3472770 DOI: 10.1101/Sqb.1986.051.01.110 |
0.357 |
|
1987 |
Dean M, Park M, Kaul K, Blair D, Woude GFV. Activation of the met proto-oncogene in a human cell line. Haematology and Blood Transfusion. 31: 464-468. PMID 3327781 DOI: 10.1007/978-3-642-72624-8_99 |
0.351 |
|
1987 |
Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude G. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proceedings of the National Academy of Sciences of the United States of America. 84: 6379-83. PMID 2819873 DOI: 10.1073/Pnas.84.18.6379 |
0.479 |
|
1986 |
Park M, Dean M, Cooper CS, Schmidt M, O'Brien SJ, Blair DG, Vande Woude GF. Mechanism of met oncogene activation. Cell. 45: 895-904. PMID 2423252 DOI: 10.1016/0092-8674(86)90564-7 |
0.351 |
|
1985 |
Dean M, Park M, Le Beau MM, Robins TS, Diaz MO, Rowley JD, Blair DG, Vande Woude GF. The human met oncogene is related to the tyrosine kinase oncogenes Nature. 318: 385-388. PMID 4069211 DOI: 10.1038/318385A0 |
0.437 |
|
Show low-probability matches. |